Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Oct 10;4(9):930-933.
doi: 10.1016/j.jdcr.2018.08.003. eCollection 2018 Oct.

Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma

Ahmed I Tahseen  1 , Neel B Patel  2
Affiliations
Case Reports

Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma

Ahmed I Tahseen et al. JAAD Case Rep. .
No abstract available

Keywords: BRAF inhibitor; BRAF inhibitor Stevens-Johnson syndrome; BRAF inhibitor toxic epidermal necrolysis; LTT, lymphocyte transformation test; NO, nitric oxide; RIP3, receptor-interacting protein kinase 3; SJS, Stevens-Johnson syndrome; Stevens-Johnson syndrome; Stevens-Johnson syndrome desensitization; TEN, toxic epidermal necrolysis; allergic reaction; antitumor response; antitumor response toxic epidermal necrolysis; coBRIM adverse effect; coBRIM allergic reaction; coBRIM hypersensitivity; coBRIM, combined cobimetinib and vemurafenib therapy; cross-reactivity; dabrafenib; dabrafenib toxic epidermal necrolysis; dabrafenib vemurafenib; dabrafenib vemurafenib switch; hypersensitivity; lymphocyte transformation test Stevens-Johnson syndrome; lymphocyte transformation test toxic epidermal necrolysis; melanoma; metastatic melanoma; sulfonamide; sulfonamide cross-reactivity; sulfonamide drug; sulfonamide toxic epidermal necrolysis; toxic epidermal necrolysis; toxic epidermal necrolysis desensitization; toxic epidermal necrolysis/Stevens-Johnson syndrome; vemurafenib; vemurafenib adverse effect; vemurafenib allergic reaction; vemurafenib dabrafenib cross-reactivity; vemurafenib hypersensitivity; vemurafenib toxic epidermal necrolysis.

PubMed Disclaimer

References

    1. McArthur G.A., Chapman P.B., Robert C. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–332. - PMC - PubMed
    1. Bellón T., Lerma V., González-Valle O. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds. Br J Dermatol. 2015;174(3):621–624. - PubMed
    1. Jeudy G., Dalac-Rat S., Bonniaud B. Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis. Br J Dermatol. 2015;172(5):1454–1455. - PubMed
    1. Curtin J.A., Fridlyand J., Kageshita T. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135–2147. - PubMed
    1. Carlos G., Anforth R., Clements A. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151(10):1103–1109. - PubMed

Publication types